nancy lynn MD snyderman
CIK 1675198 · last filed 2026-08-03
nancy lynn MD snyderman is a corporate insider who has filed 39 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for ALKS, was dated Aug 3, 2026. Across all open-market trades the lifetime net is −$2.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.75M
4
39
-$2.14M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALKS | Director | 36,178 | $48.37 | $1.75M | -$2.23M | 20 | 2026-08-03 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | 20 | $0.70 | $14 | $10.0K | 7 | 2025-05-16 |
| Axonics, Inc. (AXNX) Delisted | Director | 0 | $70.98 | $0 | $74.2K | 9 | 2024-11-15 |
| Future Health ESG Corp. (FHLTU) Delisted | Director | 22,512 | $11.15 | $251.0K | $0 | 2 | 2021-10-26 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-03 | ALKS | Notice (144) | −44,472 | -$2.24M | EDGAR |
| 2026-08-03 | ALKS | Mixed | — | -$161.3K | EDGAR |
| 2026-05-22 | ALKS | Mixed | +4,667 | -$54.5K | EDGAR |
| 2025-06-02 | ALKS | Mixed | +6,089 | -$58.9K | EDGAR |
| 2025-05-23 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2025-05-16 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-11-15 | Axonics, Inc. (AXNX) Delisted | Disp (D) | −14,944 | -$1.06M | EDGAR |
| 2024-11-12 | Axonics, Inc. (AXNX) Delisted | Gift (G) | −5,000 | $0 | EDGAR |
| 2024-07-01 | ALKS | Mixed | +4,639 | -$35.3K | EDGAR |
| 2024-06-14 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.